The study is designed to evaluate the efficacy
of CannTrust's Cannabidiol Oil Capsules in slowing Amyotrophic
Lateral Sclerosis (ALS) progression
VAUGHAN, ON, July 11, 2018 /CNW/ - CannTrust Holdings Inc.
("CannTrust" or the "Company", TSX: TRST), one of Canada's leading licensed producers of medical
cannabis, announced today that it has partnered with Australia's Gold Coast University Hospital
("Gold Coast") to conduct a randomized, double-blind,
placebo-controlled clinical trial to determine the efficacy of
CannTrust cannabidiol (CBD) oil capsules in slowing the disease
progression in patients with Amyotrophic Lateral Sclerosis (ALS) or
Motor Neuron Disease (MND). Patient safety and tolerability will
also be assessed. The study has received Research Ethics Board
approval and Australian Therapeutic Good Administration
Acknowledgement for the study drug.
The six-month study will be led by Gold Coast Neurologist, Dr.
Arman Sabet, MD. Gold Coast is one of Australia's leading tertiary referral
institutions for ALS management and Dr. Sabet has been involved in
many international clinical trials specializing in neuromuscular
disorders and stroke.
Dr. Sabet's research will also analyze the effects of CannTrust
CBD oil capsules on study participants' spasticity, pain, weight
loss and quality of life.
"ALS is a fatal disease with no known cure. This study will help
advance our understanding of the potential effects of CannTrust's
standardized CBD oil capsules on ALS/MND, both as a disease
modifying agent and as a symptomatic treatment and will become the
basis for conducting future cannabinoid and ALS clinical trials,"
said Dr. Sabet, MD, Senior Staff Specialist, Gold Coast University
Hospital.
"The rate of ALS progression is often rapid, creating high
levels of disability for patients. People diagnosed with ALS have
an average life expectancy of 2.5 years. CannTrust is proud to
participate in this important study which aims to help us better
understand the potential impact of CannTrust CBD oil capsules on
ALS and MND, so that patients might face better outcomes," said
Eric Paul, CEO, CannTrust.
About CannTrust
Since its inception in 2014, CannTrust
has led the Canadian market in producing standardized product.
As a federally regulated licensed producer, CannTrust brings
more than 40 years of pharmacy and healthcare experience to the
medical cannabis industry. CannTrust currently operates a 60,000
sq. ft. state-of-the-art hydroponic facility in Vaughan, Ontario, as well as the recently
completed 250,000 sq. ft. Phase One redevelopment of its 450,000
sq. ft. Niagara Perpetual Harvest Facility. The Phase Two expansion
is underway and is anticipated to be completed and in cultivation
by fall 2018. Phase Three construction, with an additional
projected 600,000 sq. ft., is fully funded and has begun.
CannTrust is committed to research and innovation, as well as
contributing to the growing body of evidence-based research
regarding the use and efficacy of cannabis. Our product development
teams along with our exclusive global pharma partner, Apotex Inc.,
are diligently innovating and developing products that will make it
easier for patients to use medical cannabis. We support ongoing
patient education about medical cannabis and have a compassionate
use program to support patients with financial needs. For more
information, please visit: www.canntrust.ca.
Forward Looking Statements
This press release contains
"forward-looking information" within the meaning of applicable
Canadian securities legislation which are based upon CannTrust's
current internal expectations, estimates, projections, assumptions
and beliefs and views of future events. Forward-looking information
can be identified by the use of forward-looking terminology such as
"expect", "likely", "may", "will", "should", "intend",
"anticipate", "potential", "proposed", "estimate" and other similar
words, including negative and grammatical variations thereof, or
statements that certain events or conditions "may", "would" or
"will" happen, or by discussions of strategy.
The forward-looking information in this news release is based
upon the expectations, estimates, projections, assumptions and
views of future events which management believes to be reasonable
in the circumstances. Forward-looking information includes
estimates, plans, expectations, opinions, forecasts, projections,
targets, guidance or other statements that are not statements of
fact. Forward-looking statements in this news release include, but
are not limited to, statements with respect to internal
expectations, expectations with respect to actual production
volumes, expectations for future growing capacity and the
completion of any capital project or expansions. Forward-looking
statements necessarily involve known and unknown risks, including,
without limitation, risks associated with general economic
conditions; adverse industry events; loss of markets; future
legislative and regulatory developments; inability to access
sufficient capital from internal and external sources, and/or
inability to access sufficient capital on favorable terms; the
medical cannabis industry in Canada generally; the
ability of CannTrust to implement its business strategies;
competition; crop failure; and other risks.
Any forward-looking information speaks only as of the date on
which it is made, and, except as required by law, CannTrust does
not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for CannTrust to predict all
such factors. When considering these forward-looking statements,
readers should keep in mind the risk factors and other cautionary
statements in CannTrust's Annual Information Form dated
March 29, 2018 (the "AIF") and filed
with the applicable Canadian securities regulatory authorities on
SEDAR at www.sedar.com. The risk factors and other factors noted in
the AIF could cause actual events or results to differ materially
from those described in any forward-looking information.
The TSX does not accept responsibility for the adequacy or
accuracy of this release.
Copyright © 2017 CannTrust Holdings Inc.
View original content with
multimedia:http://www.prnewswire.com/news-releases/canntrust-and-australias-gold-coast-university-hospital-partner-in-als-clinical-trial-300679084.html
SOURCE CannTrust Holdings Inc.